May 13, 2021

Goldfinch Bio

Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-024, a Novel Precision Medicine Product Candidate for Patients with Severe Insulin Resistant Diabetic Nephropathy (DN)

May 12, 2021

Voyager Therapeutics

Voyager Therapeutics Presents New Preclinical Data Showing Reduction Of Pathological Tau With Vectorized Anti-Tau Antibody

May 12, 2021

Magenta Therapeutics

Magenta Therapeutics Announces $86.4 Million Common Stock Investment From Multiple Investors

May 12, 2021

Magenta Therapeutics Announces Positive Preliminary Results From Phase 2 Clinical Trial Of MGTA-145 In Multiple Myeloma And Provides An Update On Its Anticipated Clinical Study With MGTA-117

May 12, 2021

Fulcrum Therapeutics

Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

Load More

Sign up for weekly portfolio news.